Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Bullboard (NDAQ:EDIT)

View:
Comment by Napcooon May 21, 2024 10:02pm

RE:Ruby study expected to be completed Aug 2025

https://www.globenewswire.com/news-release/2020/12/05/2140152/0/en/CRISPR-Therapeutics-and-Vertex-Present-New-Data-for-Investigational-CRISPR-Cas9-Gene-Editing-Therapy-CTX001-at-American-Society-of ...more  
3
Discussion
Post by Napcooon May 16, 2024 11:11pm

Ruby study expected to be completed Aug 2025

 https://www.clinicaltrials.gov/study/NCT04853576
65
Discussion
Comment by 0checkeron Aug 19, 2021 8:20pm

RE:Genome Therapy New Biotech Darling?

https://www.innovationnewsnetwork.com/crispr-technology-achieves-dna-repair-in-space-for-the-first-time/14184/
130
Discussion
Comment by chiefmissileon Dec 27, 2020 10:59am

RE:Genome Therapy New Biotech Darling?

  Hi there, in the recent Jeff Brown pitch for his "exponential tech investor" he talks about a small cap biotech company, now he gave away a couple of clues. The company is owned by ...more  
413
Discussion
Post by bcwildthingon Nov 03, 2020 8:48am

Genome Therapy New Biotech Darling?

Just finished getting pitched Jeff Brown's newsletter for a small cap gene therapy company. I'm not sure which is his pick, but EDIT seems close to trial results showing up. Anyone have any ...more  
367
Discussion
Post by Kanolion Jul 06, 2020 4:06pm

1st Human Clinical Trial

When is this news going to be released? They said results would be a month and we are well past that. Any insight or idea when?
181
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities